Treatment of bulimia with bupropion: a multicenter controlled trial.

Abstract

In a placebo-controlled, double-blind study of the unique antidepressant agent bupropion in the treatment of nondepressed subjects with bulimia (bupropion group, N = 55; placebo group, N = 26), we found the drug significantly superior to placebo in reducing episodes of binge eating and purging. In general, side effects with bupropion were minimal. However, four subjects experienced grand mal seizures during treatment with bupropion, a frequency of seizures far higher than observed in previous studies with this drug. Pending a satisfactory explanation for the occurrence of these seizures, we recommend that bupropion not be administered alone to bulimic patients.

• Authors: R L Horne, J M Ferguson, H G Pope Jr, J I Hudson, C G Lineberry, J Ascher, A Cato
• Journal: The Journal of clinical psychiatry (J Clin Psychiatry) Vol. 49 Issue 7 Pg. 262-6 (Jul 1988) ISSN: 0160-6689 [Print] United States
• PMID: 3134343 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article)

Chemical References

• Placebos
• Propiophenones
• Bupropion

Topics

• Adolescent
• Adult
• Ambulatory Care
• Bulimia (drug therapy)
• Bupropion
• Clinical Trials as Topic
• Double-Blind Method
• Epilepsy, Tonic-Clonic (chemically induced)
• Female
• Humans
• Middle Aged
• Outcome and Process Assessment, Health Care
• Patient Dropouts
• Placebos
• Propiophenones (adverse effects, therapeutic use)